Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Durvalumab, Durvalumab (Cohort 1-3), Durvalumab (MEDI4736), durvalumab
Durvalumab+ Chemotherapy phase · 1 trial · 1 indication
Safety and tolerability will be evaluated in terms of Adverse Events (AEs), Serious AEs (SAEs), and immune-mediated AEs (imAEs)
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | Durvalumab + Chemotherapy (chemotherapy phase) plus Durvalumab + Olaparib (maintenence phase) |
| Name | Type | Description |
|---|---|---|
| Durvalumab + Chemotherapy phase | DRUG | Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks. |
| Durvalumab + Olaparib phase | DRUG | durvalumab (IV) with olaparib (tablets) every four weeks until progression. |
INCLUSION CRITERIA Disease characteristics 3. Histologically confirmed diagnosis of endometrial carcinoma (all histologies, including carcinosarcoma) with archival or recent biopsy available to send at study entry. 4\. Only patients with pMMR tumors are allowed (mismatch repair status determined l...
Top 20 of 47 competitors
Durvalumab is an investigational antibody being studied for multiple cancers, including triple negative breast neoplasms, extensive-stage small cell lung cancer, invasive bladder cancer, metastatic non-small cell lung cancer, and non-small cell lung cancer. It is currently in Phase 3 clinical development and is not FDA approved.
Durvalumab is a monoclonal antibody (mab) that targets PD-L1, a protein that helps cancer cells evade the immune system. By blocking PD-L1, durvalumab aims to enhance the body's immune response against tumors. This mechanism is being evaluated across several oncology indications.
Durvalumab is developed by AstraZeneca PLC, a global biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting multiple clinical trials to evaluate durvalumab as a potential treatment for various solid tumors.
Durvalumab is in Phase 3 clinical development for extensive-stage small cell lung cancer and other indications. It is an investigational drug, meaning it has not yet received FDA approval. Several Phase 3 trials are ongoing or completed, with a total of 8 clinical trials registered.
Durvalumab is being studied in 8 clinical trials, including NCT03043872 (CASPIAN), a Phase 3 trial combining durvalumab with tremelimumab and chemotherapy in untreated extensive-stage small cell lung cancer. Other trials include NCT03446547, NCT04449861, and NCT04712903, all evaluating durvalumab in lung cancer settings.
Durvalumab is also known as Durvalumab/Tremelimumab Combination Therapy, referring to its use in combination with tremelimumab. It is also referred to as Durvalumab (MEDI4736), Durvalumab + Chemotherapy, and SC durvalumab + rHu. These names describe different regimens or formulations of the same drug.